NEW YORK (GenomeWeb News) – IntelligentMDx today said that the US Food and Drug Administration has cleared its C. difficile assay for the Abbott m2000 system.

The assay, the third to receive FDA clearance for use on Abbott's platform in the past three months, detects nucleic acids encoding the toxin A gene and toxin B gene sequences of toxigenic strains of Clostridium difficile in human liquid or soft stool specimens in patients suspected of having C. difficile-associated illnesses.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.